Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Edwards’ latest-generation balloon-expandable transcatheter heart valve incorporates a proprietary calcification-resistant tissue technology
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
The partnership combines Boehringer’s expertise in canine cardiology with Eko’s digital stethoscopes and AI algorithms
Subscribe To Our Newsletter & Stay Updated